- Home
- REPX vs SGP Comparison
REPX vs SGP Comparison
Compare REPX & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REPX | SGP |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | United States |
| Employees | N/A | 65 |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 776.6M | 650.9M |
| IPO Year | 2003 | N/A |
Fundamental Metrics
Financial Performance| Metric | REPX | SGP |
|---|---|---|
| Price | $32.51 | $19.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $45.00 | $45.00 |
| AVG Volume (30 Days) | ★ 250.9K | 138.6K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.41% | N/A |
| EPS Growth | ★ 78.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,038,000.00 | N/A |
| Revenue This Year | $33.41 | N/A |
| Revenue Next Year | $13.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.08 | $17.06 |
| 52 Week High | $41.53 | $30.56 |
Technical Indicators
Market Signals| Indicator | REPX | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 45.75 |
| Support Level | $32.30 | $17.33 |
| Resistance Level | $36.85 | $20.25 |
| Average True Range (ATR) | 1.14 | 1.44 |
| MACD | -0.07 | 0.29 |
| Stochastic Oscillator | 12.06 | 36.41 |
Price Performance
Historical ComparisonAbout REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations include: The Permian Basin is an oil and natural gas producing area located in West Texas.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.